title: Inhibition of rat lipoprotein oxidation after tetradecylthioacetic acid feeding.
abstract: We have previously shown that tetradecylthioacetic acid (TTA), a sulfur containing saturated fatty acid analogue, inhibits the oxidative modification of human low-density lipoprotein (LDL) in vitro. The oxidative modification of LDL is believed to be a crucial step in the progression of atherosclerosis. In the present study, we investigated the effect of TTA oral administration on the susceptibility of rat lipoprotein to undergo oxidative modification ex vivo. Lipoprotein resistance to copper-induced oxidation was highly improved after TTA administration to rats. Conjugated dienes produced after 150 min of lipoprotein oxidation were dramatically lowered in the TTA treated rats compared to controls. Malondialdehyde and lipid peroxides production by oxidation was highly limited. These effects were independent of any Vitamin E effects. More than 50% relative reduction in polyunsaturated fatty acids of the n-3 family, and more than 30% relative increase in 18:1n-9 fatty acid in the triacylglycerol (TAG)-rich lipoprotein were observed. TAG-rich lipoprotein lipids of TTA fed rats were decreased with more than 50% reduction in TAG. The data reported in this paper indicate a potent in vivo antioxidant capability of TTA that beside its hypolipidemic effect might be of importance in relation to the development of atherosclerosis.
authors.affiliation: Institute of Clinical Biochemistry, Haukeland University Hospital, University of Bergen, N-5021 Bergen, Norway. ziad.muna@ikb.uib.no
authors.forename: Ziad A
authors.initials: ZA
authors.lastname: Muna
authors.forename: Oddrun A
authors.initials: OA
authors.lastname: Gudbrandsen
authors.forename: Hege
authors.initials: H
authors.lastname: Wergedahl
authors.forename: Pavol
authors.initials: P
authors.lastname: Bohov
authors.forename: Jon
authors.initials: J
authors.lastname: Skorve
authors.forename: Rolf K
authors.initials: RK
authors.lastname: Berge
mesh_terms: D000818:Animals; D004347:Drug Interactions; D005227:Fatty Acids / Q000032:analysis; D050356:Lipid Metabolism; D008074:Lipoproteins / Q000378:metabolism*; D008075:Lipoproteins, HDL / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008297:Male; D023421:Models, Animal; D010084:Oxidation-Reduction / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013440:Sulfides / Q000494:pharmacology*; D014280:Triglycerides / Q000378:metabolism; D014810:Vitamin E / Q000494:pharmacology
chemical_list: D005227:Fatty Acids; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D013440:Sulfides; D014280:Triglycerides; D014810:Vitamin E; C062078:1-(carboxymethylthio)tetradecane